Evaluating antibiotic treatment duration for community-acquired pneumonia
Adherence to Clinical Guidelines Regarding the Duration of Antibiotic Treatment in Patients Hospitalized for Community-acquired Pneumonia With Clinical sTability. ADAPT Study
This study is testing whether reminding doctors to follow guidelines on how long to give antibiotics can help patients with mild pneumonia get better while using fewer unnecessary antibiotics.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 2000 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | Instituto de Investigacion Sanitaria La Fe Academic / other |
| Locations | 1 site (Valencia) |
| Trial ID | NCT05762328 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to assess adherence to clinical guidelines regarding the duration of antibiotic treatment in patients hospitalized for non-severe community-acquired pneumonia (CAP) who have reached clinical stability. The study will be conducted over two years, with the first year focusing on observational data collection to evaluate current practices. In the second year, interventions will be implemented to remind clinicians to adhere to recommended treatment durations, thereby aiming to reduce unnecessary antibiotic use. The trial will involve multiple centers to gather a diverse patient population.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years hospitalized for community-acquired pneumonia with clinical stability after at least 3 days of antibiotic treatment.
Not a fit: Patients with severe pneumonia requiring intensive care, or those with specific exclusions such as active tuberculosis or immunosuppression, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more appropriate antibiotic use, reducing side effects and antibiotic resistance in patients with community-acquired pneumonia.
How similar studies have performed: Previous studies have shown that adherence to clinical guidelines can improve patient outcomes, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients \>18 years hospitalized for community-acquired pneumonia with a new infiltrate on chest X-ray and/or computerized tomography. * At least one compatible sign or symptom (fever, cough, expectoration, dyspnea, chest pain or crackles on auscultation) * Correctly treated with ≥ 3 days of antibiotic Exclusion Criteria: * Intensive care unit admission during the first 5 days since hospital admission * Abscess or necrotizing pneumonia * Empyema or pleural effusion requiring drainage tube * Bronchiectasis * Cystic fibrosis * Active tuberculosis * Postobstructive pneumonia * Suspected bronchial aspiration * SARS-CoV-2 infection * Immunosuppression (congenital immunodeficiencies, HIV infection, solid organ transplantation, functional or anatomical asplenia, immunosuppressive treatment, active solid or haematological neoplasia \[active treatment in the last 12 months\], etc.) * Hospital acquired pneumonia * Concomitant extrapulmonary infection that requires antibiotic treatment for more than 5 days (eg myocarditis) * Confirmed diagnosis alternative to pneumonia (eg, lung cancer)
Where this trial is running
Valencia
- University and Polytechnic Hospital La Fe — Valencia, Spain (Recruiting)
Study contacts
- Principal investigator: Raúl Méndez, MD, PhD — Instituto de Investigación Sanitaria La Fe
- Study coordinator: Raúl Méndez, MD, PhD
- Email: rmendezalcoy@gmail.com
- Phone: +34 961244000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.